The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
mTOR-targeted therapy of cancer with rapamycin derivatives
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., Belham, C., & Avruch, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14484 · Cited by 1,367
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Mammalian TOR: a homeostatic ATP sensor
Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S. C., & Thomas, G. (2001) · Science · doi:10.1126/science.1063518 · Cited by 962
SEHGAL, S. N., BAKER, H., & VÉZINA, C. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.727 · Cited by 947
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Sirolimus: its discovery, biological properties, and mechanism of action
Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 779
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Marsh, D. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.3.507 · Cited by 653
Dijkers, P. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S. B., Lam, E. W.-F., Burgering, B. M. T., Raaijmakers, J. A. M., Lammers, J.-W. J., Koenderman, L., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9138-9148.2000 · Cited by 617
Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient Uptake
Edinger, A. L., & Thompson, C. B. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-12-0584 · Cited by 589
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo
Schuler, W., Sedrani, R., Cottens, S., H??berlin, B., Schulz, M., Schuurman, H.-J., Zenke, G., Zerwes, H.-G., & Schreier, M. H. (1997) · Transplantation · doi:10.1097/00007890-199707150-00008 · Cited by 533
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 528
Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase
Ui, M., Okada, T., Hazeki, K., & Hazeki, O. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89056-8 · Cited by 520
Rapamycin inhibits vascular smooth muscle cell migration.
Poon, M., Marx, S. O., Gallo, R., Badimon, J. J., Taubman, M. B., & Marks, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119038 · Cited by 511
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Self-citationGallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Koller, W. C., Lyons, K., Pahwa, R., & Sf, S. W. (2002) · Cited by 421
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Humar, R., Kiefer, F. N., Berns, H., Resink, T. J., & Battegay, E. J. (2002) · The FASEB Journal · doi:10.1096/fj.01-0658com · Cited by 381
Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., & Houghton, P. J. (1999) · PubMed · Cited by 356
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
Boulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O’Reilly, T., Stolz, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3554-2 · Cited by 318
Clinical Pharmacokinetics of Sirolimus
Mahalati, K., & Kahan, B. D. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00002 · Cited by 302
Pene, F., Claessens, Y.-E., Muller, O., Viguié, F., Mayeux, P., Dreyfus, F., Lacombe, C., & Bouscary, D. (2002) · Oncogene · doi:10.1038/sj.onc.1205923 · Cited by 295
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M.-C., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 285
Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K
Kozma, S. C., & Thomas, G. (2002) · BioEssays · doi:10.1002/bies.10031 · Cited by 284
Ma, K. (2000) · PubMed · Cited by 276
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
Gao, N., Zhang, Z., Jiang, B.-H., & Shi, X. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.132 · Cited by 275
Davies, M. A., Lu, Y., Sano, T., Fang, X., Tang, P., LaPushin, R., Koul, D., Bookstein, R., Stokoe, D., Yung, W. K. A., et al. (1998) · PubMed · Cited by 270
Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Synergism with Cyclosporine
Schuurman, H.-J., Cottens, S., Fuchs, S., Joergensen, J., Meerloo, T., Sedrani, R., Tanner, M., Zenke, G., & Schuler, W. (1997) · Transplantation · doi:10.1097/00007890-199707150-00007 · Cited by 248
TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin
Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 238
Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi, Y., Gera, J., Hu, L., Hsu, J.-H., Bookstein, R., Li, W., & Lichtenstein, A. K. (2002) · PubMed · Cited by 231
Buscà, R., Bertolotto, C., Ortonne, J.-P., & Ballotti, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31824 · Cited by 231
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
Kahan, B. D., & Camardo, J. S. (2001) · Transplantation · doi:10.1097/00007890-200110150-00001 · Cited by 225
PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.
Paez, J., & Sellers, W. R. (2003) · PubMed · Cited by 213
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210
Majewski, M., Korecka, M., Kossev, P., Li, S., Goldman, J., Moore, J., Silberstein, L. E., Nowell, P. C., Schuler, W., Shaw, L. M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080068597 · Cited by 210
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209
Xu, G., Kwon, G., Cruz, W. S., Marshall, C. A., & McDaniel, M. L. (2001) · Diabetes · doi:10.2337/diabetes.50.2.353 · Cited by 207
Grant, S. (2002) · Frontiers in Bioscience · doi:10.2741/grant · Cited by 202
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba, J. M., deGraffenried, L. A., Friedrichs, W. E., Fulcher, L. C., Grünwald, V., Weiss, G. R., & Hidalgo, M. M. (2003) · PubMed · Cited by 191
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang, S., & Houghton, P. J. (2002) · PubMed · Cited by 186
Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
Andoh, T. F., Burdmann, E. A., Fransechini, N., Houghton, D. C., & Bennett, W. M. (1996) · Kidney International · doi:10.1038/ki.1996.417 · Cited by 186
Takuwa, N., Fukui, Y., & Takuwa, Y. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1346 · Cited by 182
Paez, J., & Sellers, W. R. (2006) · Cancer Treatment and Research · doi:10.1007/0-306-48158-8_6 · Cited by 180
R.‐Borlado, L., Redondo, C., Alvarez, B., Jimenez, C., Criado, L. M., Flores, J., Marcos, M. A. R., Martinez‐A., C., Balomenos, D., & Carrera, A. C. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.895 · Cited by 175
Blaha, P., Bigenzahn, S., Koporc, Z., Schmid, M., Langer, F., Selzer, E., Bergmeister, H., Wrba, F., Kurtz, J., Kiss, C., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3014 · Cited by 175
Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells
Hosoi, H., Dilling, M. B., Liu, L. N., Danks, M. K., Shikata, T., Sekulic, A., Abraham, R. T., Lawrence, J. C., & Houghton, P. J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.5.815 · Cited by 172
Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.
BAKER, H., SIDOROWICZ, A., SEHGAL, S. N., & VÉZINA, C. (1978) · The Journal of Antibiotics · doi:10.7164/antibiotics.31.539 · Cited by 166
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV‐1 envelope
Castedo, M., Roumier, T., Blanco, J., Ferri, K. F., Barretina, J., Tintignac, L. A. J., Andréau, K., Perfettini, J., Amendola, A., Nardacci, R., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf391 · Cited by 165
Wiederrecht, G. J., Sabers, C. J., Brunn, G. J., Martin, M. M., Dumont, F. J., & Abraham, R. T. (1995) · Progress in Cell Cycle Research · doi:10.1007/978-1-4615-1809-9_5 · Cited by 164
Wu, L., Birle, D. C., & Tannock, I. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3137 · Cited by 164
Reitamo, S., Spuls, P. I., Sassolas, B., Lahfa, M., Claudy, A., Griffiths, C. E. M., & FOR THE SIROLIMUS EUROPEAN PSORIASIS STUDY GROUP (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04376.x · Cited by 161
Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer
Mita, M. M., Mita, A. C., & Rowinsky, E. K. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.018 · Cited by 145
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update
Trepanier, D. J., Gallant, H. L., LeGatt, D. F., et al. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00048-4 · Cited by 137
Rapamycin: Distribution, Pharmacokinetics, and Therapeutic Range Investigations
Yatscoff, R. W., Wang, P. C., Chan, K., et al. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00020 · Cited by 135
Clinically Significant Drug Interactions with New Immunosuppressive Agents
Mignat, C. (1997) · Drug Safety · doi:10.2165/00002018-199716040-00004 · Cited by 133
Punt, C. J. A., Boni, J. P., Bruntsch, U., Peters, M. E. W. J., & Thielert, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg248 · Cited by 121
Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action.
Singh, K., Sun, S., & Vézina, C. (1979) · The Journal of Antibiotics · doi:10.7164/antibiotics.32.630 · Cited by 119
Neve, R. M., Holbro, T., & Hynes, N. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205555 · Cited by 114
Ikonen, T. S., Gummert, J. F., Hayase, M., Honda, Y., Hausen, B., Christians, U., Berry, G. J., Yock, P. G., & Morris, R. E. (2000) · Transplantation · doi:10.1097/00007890-200009270-00015 · Cited by 110
Heesom, K. J., & Denton, R. M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01094-7 · Cited by 99
Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., & Houghton, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110782200 · Cited by 98
MDA-7 negatively regulates the β-catenin and PI3K signaling pathways in breast and lung tumor cells
Mhashilkar, A. M., Stewart, A., Sieger, K., Yang, H.-Y., Khimani, A. H., Ito, I., Saito, Y., Hunt, K. K., Grimm, E. A., Roth, J. A., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00170-9 · Cited by 89
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Self-citationMcLeod, L. E., & Proud, C. G. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03582-2 · Cited by 72
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells
Fruman, D. A., Wood, M. A., Gjertson, C. K., Katz, H. R., Burakoff, S. J., & Bierer, B. E. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250239 · Cited by 72
Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase
Calastretti, A., Bevilacqua, A., Ceriani, C., Viganò, S., Zancai, P., Capaccioli, S., & Nicolin, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204751 · Cited by 62
EFFECTS OF RAPAMYCIN IN EXPERIMENTAL ORGAN ALLOGRAFTING
Ochiai, T., Gunji, Y., Nagata, M., KOMORI, A., Asano, T., & Isono, K. (1993) · Transplantation · doi:10.1097/00007890-199307000-00003 · Cited by 59
A novel conditional Akt ‘survival switch’ reversibly protects cells from apoptosis
LI, B., Desai, S., MacCorkle-Chosnek, R., Fan, L.-W., & Spencer, D. M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301641 · Cited by 50
Elit, L. M. (2002) · PubMed · Cited by 43
Brattström, C., Tydén, G., Säwe, J., Herlenius, G., Claesson, K., & Cg, G. (1996) · PubMed · Cited by 34
Therapeutic Monitoring of Rapamycin
Yatscoff, R. W., LeGatt, D. F., & Kneteman, N. M. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199312000-00004 · Cited by 31
Renal effects of rapamycin in the spontaneously hypertensive rat
DiJoseph, J. F., Mihatsch, M. J., & Sehgal, S. N. (1994) · Transplant International · doi:10.1007/bf00336467 · Cited by 29
Use of rapamycin-impregnated stents in coronary arteries
Sousa, J. E., Sousa, A. G. M. R., Costa, M. A., Abizaid, A., & Feres, F. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00215-x · Cited by 24
DAVIES, C. B., Madden, R., ALEXANDER, J. W., Cofer, B. R., FISHER, R. A., & ANDERSON, P. (1993) · Transplantation · doi:10.1097/00007890-199305000-00033 · Cited by 23
Inhibitory effect of wortmannin on phosphatidylinositol 3-kinase-mediated cellular events
Hazeki, O., Hazeki, K., Katada, T., & Ui, M. (1996) · Journal of Lipid Mediators and Cell Signalling · doi:10.1016/0929-7855(96)00534-2 · Cited by 23
Metcalf, C. A., Bohacek, R. S., Rozamus, L. W., Burns, K. D., Roses, J. B., Rivera, V. M., Tang, H., Keats, J. A., Dalgarno, D. C., Snodgrass, J. T., et al. (2004) · Cancer Research · Cited by 22
Cited by
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Self-citationEfficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
Adams, D. M., Trenor, C. C., Hammill, A. M., Vinks, A. A., Patel, M. N., Chaudry, G., Wentzel, M. S., Mobberley-Schuman, P. S., Campbell, L. M., Brookbank, C., et al. (2016) · Pediatrics · doi:10.1542/peds.2015-3257 · Cited by 844
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Metadata
- Authors
- Vignot, S., Faivre, S., Aguirre, D., & Raymond, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 16
- Issue
- 4
- Pages
- 525-537
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2113365503
- Cited by
- 617
- References
- 90
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.